{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T20:08:06Z","timestamp":1788811686796,"version":"build-2803163510"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>While Type 1 Diabetes Mellitus (T1DM) is characterized by hypoinsulinemia and hyperglycemia, persons with T1DM also develop insulin resistance. Recent studies have demonstrated that insulin resistance in T1DM is a primary mediator of the micro and macrovascular complications that invariably develop in this chronic disease. Myostatin acts to attenuate muscle growth and has been demonstrated to be elevated in streptozotocin-induced diabetic models. We hypothesized that a reduction in mRNA expression of myostatin within a genetic T1DM mouse model would improve skeletal muscle health, resulting in a larger, more insulin sensitive muscle mass. To that end, Akita diabetic mice were crossed with Myostatin<jats:sup>Ln\/Ln<\/jats:sup> mice to ultimately generate a novel mouse line. Our data support the hypothesis that decreased skeletal muscle expression of myostatin mRNA prevented the loss of muscle mass observed in T1DM. Furthermore, reductions in myostatin mRNA increased Glut1 and Glut4 protein expression and glucose uptake in response to an insulin tolerance test (ITT). These positive changes lead to significant reductions in resting blood glucose levels as well as pronounced reductions in associated diabetic symptoms, even in the absence of exogenous insulin. Taken together, this study provides a foundation for considering myostatin inhibition as an adjuvant therapy in T1DM as a means to improve insulin sensitivity and blood glucose management.<\/jats:p>","DOI":"10.1038\/srep32495","type":"journal-article","created":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T10:41:52Z","timestamp":1472726512000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Myostatin inhibition therapy for insulin-deficient type 1 diabetes"],"prefix":"10.1038","volume":"6","author":[{"given":"Samantha K.","family":"Coleman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irena A.","family":"Rebalka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna M.","family":"D\u2019Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namita","family":"Deodhare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric M.","family":"Desjardins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Hawke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,9,1]]},"reference":[{"key":"BFsrep32495_CR1","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1152\/physrev.00045.2011","volume":"93","author":"JM Forbes","year":"2013","unstructured":"Forbes, J. M. & Cooper, M. E. Mechanisms of diabetic complications. Physiol. Rev. 93, 137\u2013188 (2013).","journal-title":"Physiol. Rev."},{"key":"BFsrep32495_CR2","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1001\/jama.2014.16425","volume":"313","author":"SJ Livingstone","year":"2015","unstructured":"Livingstone, S. J. et al. Scottish diabetes research network epidemiology group; Scottish renal registry. Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008\u20132010. JAMA 313, 37\u201344 (2015).","journal-title":"JAMA"},{"key":"BFsrep32495_CR3","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1056\/NEJM198607243150404","volume":"315","author":"H Yki-J\u00e4rvinen","year":"1986","unstructured":"Yki-J\u00e4rvinen, H. & Koivisto, V. A. Natural course of insulin resistance in type I diabetes. N. Engl. J. Med. 315, 224\u2013230 (1986).","journal-title":"N. Engl. J. Med."},{"key":"BFsrep32495_CR4","doi-asserted-by":"publisher","first-page":"707","DOI":"10.2337\/dc06-1982","volume":"30","author":"ES Kilpatrick","year":"2007","unstructured":"Kilpatrick, E. S., Rigby, A. S. & Atkin, S. L. Insulin resistance, the metabolic syndrome and complication risk in type 1 diabetes: \u201cdouble diabetes\u201d in the diabetes control and complications trial. Diabetes Care 30, 707\u2013712 (2007).","journal-title":"Diabetes Care"},{"key":"BFsrep32495_CR5","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1136\/bmj.2.5597.81","volume":"2","author":"FI Martin","year":"1968","unstructured":"Martin, F. I. & Stocks, A. E. Insulin sensitivity and vascular disease in insulin-dependent diabetics. Br. Med. J. 2, 81\u201382 (1968).","journal-title":"Br. Med. J."},{"key":"BFsrep32495_CR6","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1007\/s00125-013-2904-2","volume":"56","author":"SJ Cleland","year":"2013","unstructured":"Cleland, S. J., Fisher, B. M., Colhoun, H. M., Sattar, N. & Petrie, J. R. Insulin resistance in type 1 diabetes: what is \u2018double diabetes\u2019 and what are the risks? Diabetologia 56, 1462\u20131470 (2013).","journal-title":"Diabetologia"},{"key":"BFsrep32495_CR7","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1530\/EJE-14-0911","volume":"173","author":"E Donga","year":"2015","unstructured":"Donga, E., Dekkers, O. M., Corssmit, E. P. & Romijn, J. A. Insulin resistance in patients with type 1 diabetes assessed by glucose clamp studies: systematic review and meta-analysis. Eur. J. Endocrinol. 173, 101\u2013109 (2015).","journal-title":"Eur. J. Endocrinol."},{"key":"BFsrep32495_CR8","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1056\/NEJM198607243150402","volume":"315","author":"SA Amiel","year":"1986","unstructured":"Amiel, S. A., Sherwin, R. S., Simonson, D. C., Lauritano, A. A. & Tamborlane, W. V. Impaired insulin action in puberty. A contributing factor to poor glycemic control in adolescents with diabetes. N. Engl. J. Med. 315, 215\u2013219 (1986).","journal-title":"N. Engl. J. Med."},{"key":"BFsrep32495_CR9","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.2337\/diabetes.50.6.1371","volume":"50","author":"P P-eltoniemi","year":"2001","unstructured":"P-eltoniemi, P. et al. Resistance to exercise-induced increase in glucose uptake during hyperinsulinemia in insulin-resistant skeletal muscle of patients with type 1 diabetes. Diabetes 50, 1371\u20131377 (2001).","journal-title":"Diabetes"},{"key":"BFsrep32495_CR10","doi-asserted-by":"publisher","first-page":"306","DOI":"10.2337\/db10-0328","volume":"60","author":"IE Schauer","year":"2011","unstructured":"Schauer, I. E. et al. Insulin resistance, defective insulin-mediated fatty acid suppression and coronary artery calcification in subjects with and without type 1 diabetes: the CACTI study. Diabetes 60, 306\u2013314 (2011).","journal-title":"Diabetes"},{"key":"BFsrep32495_CR11","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1210\/jc.2009-1756","volume":"95","author":"KJ Nadeau","year":"2010","unstructured":"Nadeau, K. J. et al. Insulin resistance in adolescents with type 1 diabetes and Its relationship to cardiovascular function. J. ClinEndocr. Metab. 95, 513\u2013521 (2010).","journal-title":"J. ClinEndocr. Metab."},{"key":"BFsrep32495_CR12","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2174\/187153007780059423","volume":"7","author":"J Ye","year":"2007","unstructured":"Ye, J. Role of insulin in the pathogenesis of free fatty acid-induced insulin resistance in skeletal muscle. Endocr. Metab. Immune Disord. Drug Targets. 7, 65\u201374 (2007).","journal-title":"Endocr. Metab. Immune Disord. Drug Targets."},{"key":"BFsrep32495_CR13","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1210\/er.2006-0031","volume":"28","author":"A Wullaert","year":"2007","unstructured":"Wullaert, A., van Loo, G., Heyninck, K. & Beyaert, R. Hepatic tumor necrosis factor signaling and nuclear factor-kappaB: effects on liver homeostasis and beyond. Endocr. Rev. 28, 365\u2013386 (2007).","journal-title":"Endocr. Rev."},{"key":"BFsrep32495_CR14","doi-asserted-by":"publisher","first-page":"674","DOI":"10.2174\/156652407782564408","volume":"7","author":"H Kaneto","year":"2007","unstructured":"Kaneto, H. et al. Oxidative stress and the JNK pathway are involved in the development of type 1 and type 2 diabetes. Curr. Mol. Med. 7, 674\u2013686 (2007).","journal-title":"Curr. Mol. Med."},{"key":"BFsrep32495_CR15","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/nrendo.2014.29","volume":"10","author":"M Laakso","year":"2014","unstructured":"Laakso, M. & Kuusisto, J. Insulin resistance and hyperglycaemia in cardiovascular disease development. Nat. Rev. Endocrinol. 10, 293\u2013302 (2014).","journal-title":"Nat. Rev. Endocrinol."},{"key":"BFsrep32495_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0026-0495(75)90002-5","volume":"24","author":"FIR Martin","year":"1975","unstructured":"Martin, F. I. R. & Warne, G. L. Factors influencing the prognosis of vascular disease in insulin-deficient diabetics of long duration: a seven-year follow-up. Metabolism 24, 1\u20139 (1975).","journal-title":"Metabolism"},{"key":"BFsrep32495_CR17","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/BF00274219","volume":"30","author":"FIR Martin","year":"1987","unstructured":"Martin, F. I. R. & Hopper, J. L. The relationship of acute insulin sensitivity to the progression of vascular disease in long-term type 1 (insulin-dependent) diabetes mellitus. Diabetologia 30, 149\u2013153 (1987).","journal-title":"Diabetologia"},{"key":"BFsrep32495_CR18","doi-asserted-by":"publisher","first-page":"610","DOI":"10.2337\/diacare.21.4.610","volume":"21","author":"JR Erbey","year":"1998","unstructured":"Erbey, J. R., Kuller, L. H., Becker, D. J. & Orchard, T. J. The association between a family history of type 2 diabetes and coronary artery disease in a type 1 diabetes population. Diabetes Care 21, 610\u2013614 (1998).","journal-title":"Diabetes Care"},{"key":"BFsrep32495_CR19","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/(SICI)1096-9136(199805)15:5<418::AID-DIA604>3.0.CO;2-P","volume":"15","author":"G Roglic","year":"1998","unstructured":"Roglic, G. et al. Parental history of hypertension and parental history of diabetes and microvascular complications in insulin-dependent diabetes mellitus: the EURODIAB IDDM complications study. Diabet. Med. 15, 418\u2013426 (1998).","journal-title":"Diabet. Med."},{"key":"BFsrep32495_CR20","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1161\/CIRCULATIONAHA.111.077487","volume":"127","author":"JQ Purnell","year":"2013","unstructured":"Purnell, J. Q., Zinman, B. & Brunzell, J. D. The effect of excess weight gain with intensive diabetes mellitus treatment on cardiovascular disease risk factors and atherosclerosis in type 1 diabetes mellitus: results from the diabetes control and complications trial\/epidemiology of diabetes interventions and complications study (DCCT\/EDIC) study. Circulation 127, 180\u2013187 (2013).","journal-title":"Circulation"},{"key":"BFsrep32495_CR21","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.jpeds.2012.07.036","volume":"162","author":"BJ Specht","year":"2013","unstructured":"Specht, B. J. et al. Estimated insulin sensitivity and cardiovascular disease risk factors in adolescents with and without type 1 diabetes. J. Pediatr. 162, 297\u2013301 (2013).","journal-title":"J. Pediatr."},{"key":"BFsrep32495_CR22","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1136\/bmj.2.5597.81","volume":"2","author":"FI Martin","year":"1968","unstructured":"Martin, F. I. & Stocks, A. E. Insulin sensitivity and vascular disease in insulin-dependent diabetics. Br. Med. J. 2, 81\u201382 (1968).","journal-title":"Br. Med. J."},{"key":"BFsrep32495_CR23","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/387083a0","volume":"387","author":"AC McPherron","year":"1997","unstructured":"McPherron, A. C., Lawler, A. M. & Lee, S. J. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature 387, 83\u201390 (1997).","journal-title":"Nature"},{"key":"BFsrep32495_CR24","doi-asserted-by":"publisher","first-page":"e37236","DOI":"10.1371\/journal.pone.0037236","volume":"7","author":"C Brandt","year":"2012","unstructured":"Brandt, C. et al. Plasma and muscle myostatin in relation to type 2 diabetes. PLoS One 7, e37236 (2012).","journal-title":"PLoS One"},{"key":"BFsrep32495_CR25","doi-asserted-by":"publisher","first-page":"E3007","DOI":"10.1152\/ajpendo.00398.2011","volume":"302","author":"JJ Hulmi","year":"2012","unstructured":"Hulmi, J. J., Silvennoinen, M., Lehti, M., Kivel\u00e4, R. & Kainulainen, H. Altered REDD1, myostatin and Akt\/mTOR\/FoxO\/MAPK signaling in streptozotocin-induced diabetic muscle atrophy. Am. J. Physiol. Endocrinol. Metab. 302, E3007\u2013E3015 (2012).","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"BFsrep32495_CR26","doi-asserted-by":"publisher","first-page":"5784","DOI":"10.1074\/jbc.M113.483115","volume":"289","author":"S Sriram","year":"2014","unstructured":"Sriram, S. et al. Myostatin induces DNA damage in skeletal muscle of streptozotocin-induced type 1 diabetic mice. J. Biol. Chem. 289, 5784\u20135798 (2014).","journal-title":"J. Biol. Chem."},{"key":"BFsrep32495_CR27","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1038\/aps.2013.67","volume":"34","author":"J Jeong","year":"2013","unstructured":"Jeong, J., Conboy, M. J. & Conboy, I. M. Pharmacological inhibition of myostatin\/TGF-\u03b2 receptor\/pSmad3 signaling rescues muscle regenerative responses in mouse model of type 1 diabetes. Acta. Pharmacol. Sin. 34, 1052\u20131060 (2013).","journal-title":"Acta. Pharmacol. Sin."},{"key":"BFsrep32495_CR28","doi-asserted-by":"publisher","first-page":"199","DOI":"10.7150\/ijbs.10430","volume":"11","author":"Q Wang","year":"2015","unstructured":"Wang, Q., Guo, T., Portas, J. & McPherron, A. C. A soluble activin receptor type IIb does not improve blood glucose in streptozotocin-treated mice. Int. J. Biol. Sci. 11, 199\u2013208 (2015).","journal-title":"Int. J. Biol. Sci."},{"key":"BFsrep32495_CR29","doi-asserted-by":"publisher","first-page":"E814","DOI":"10.1152\/ajpendo.00586.2013","volume":"306","author":"ME Cleasby","year":"2014","unstructured":"Cleasby, M. E. et al. Local overexpression of the myostatin propeptide increases glucose transporter expression and enhances skeletal muscle glucose disposal. Am. J. Physiol. Endocrinol. Metab. 306, E814\u2013E823 (2014).","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"BFsrep32495_CR30","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.2337\/db11-0915","volume":"61","author":"T Guo","year":"2012","unstructured":"Guo, T. et al. Myostatin inhibition prevents diabetes and hyperphagia in a mouse model of lipodystrophy. Diabetes 61, 2414\u20132423 (2012).","journal-title":"Diabetes"},{"key":"BFsrep32495_CR31","doi-asserted-by":"publisher","first-page":"e4937","DOI":"10.1371\/journal.pone.0004937","volume":"4","author":"T Guo","year":"2009","unstructured":"Guo, T. et al. Myostatin inhibition in muscle, but not adipose tissue, decreases fat mass and improves insulin sensitivity. PLoS One 4, e4937 (2009).","journal-title":"PLoS One"},{"key":"BFsrep32495_CR32","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.bbrc.2005.09.044","volume":"337","author":"B Zhao","year":"2005","unstructured":"Zhao, B., Wall, R. J. & Yang, J. Transgenic expression of myostatin propeptide prevents diet-induced obesity and insulin resistance. Biochem. Biophys. Res. Commun. 337, 248\u2013255 (2005).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"BFsrep32495_CR33","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.2337\/db08-0245","volume":"58","author":"JJ Wilkes","year":"2009","unstructured":"Wilkes, J. J., Lloyd, D. J. & Gekakis, N. Loss-of-function mutation in myostatin reduces tumor necrosis factor alpha production and protects liver against obesity-induced insulin resistance. Diabetes 58, 1133\u20131143 (2009).","journal-title":"Diabetes"},{"key":"BFsrep32495_CR34","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1152\/japplphysiol.91565.2008","volume":"106","author":"MP Krause","year":"2009","unstructured":"Krause, M. P. et al. Diabetic myopathy differs between Ins2Akita+\/\u2212 and streptozotocin-induced type 1 diabetic models. J. Appl. Physiol. 106, 1650\u20131659 (2009).","journal-title":"J. Appl. Physiol."},{"key":"BFsrep32495_CR35","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/BF00220185","volume":"162","author":"RB Armstrong","year":"1975","unstructured":"Armstrong, R. B., Gollnick, P. D. & Ianuzzo, C. D. Histochemical properties of skeletal muscle fibers in streptozotocin-diabetic rats. Cell Tissue Res. 162, 387\u2013394 (1975).","journal-title":"Cell Tissue Res."},{"key":"BFsrep32495_CR36","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1002\/ar.1092390104","volume":"239","author":"KM Klueber","year":"1994","unstructured":"Klueber, K. M. & Feczko, J. D. Ultrastructural, histochemical and morphometric analysis of skeletal muscle in a murine model of type I diabetes. Anat. Rec. 239, 18\u201334 (1994).","journal-title":"Anat. Rec."},{"key":"BFsrep32495_CR37","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1002\/mus.20175","volume":"31","author":"S Girgenrath","year":"2005","unstructured":"Girgenrath, S., Song, K. & Whittemore, L. A. Loss of myostatin expression alters fiber-type distribution and expression of myosin heavy chain isoforms in slow-and fast-type skeletal muscle. Muscle Nerve 31, 34\u201340 (2005).","journal-title":"Muscle Nerve"},{"key":"BFsrep32495_CR38","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1073\/pnas.0604893104","volume":"104","author":"H Amthor","year":"2007","unstructured":"Amthor, H. et al. Lack of myostatin results in excessive muscle growth but impaired force generation. Proc. Natl. Acad. Sci. USA 104, 1835\u20131840 (2007).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFsrep32495_CR39","doi-asserted-by":"publisher","first-page":"C525","DOI":"10.1152\/ajpcell.00259.2007","volume":"296","author":"A Hennebry","year":"2009","unstructured":"Hennebry, A. et al. Myostatin regulates fiber-type composition of skeletal muscle by regulating MEF2 and MyoD gene expression. Am. J. Physiol. Cell Physiol. 296, C525\u2013C534 (2009).","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"BFsrep32495_CR40","doi-asserted-by":"publisher","first-page":"4813","DOI":"10.1073\/pnas.0909422107","volume":"107","author":"MY Wang","year":"2010","unstructured":"Wang, M. Y. et al. Leptin therapy in insulin-deficient type I diabetes. Proc. Natl. Acad. Sci. USA 107, 4813\u20134819 (2010).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFsrep32495_CR41","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s00125-011-2304-4","volume":"55","author":"C Zhang","year":"2012","unstructured":"Zhang, C. et al. Inhibition of myostatin protects against diet-induced obesity by enhancing fatty acid oxidation and promoting a brown adipose phenotype in mice. Diabetologia 55, 183\u2013193 (2012).","journal-title":"Diabetologia"},{"key":"BFsrep32495_CR42","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1096\/fj.12-225755","volume":"27","author":"T Shan","year":"2013","unstructured":"Shan, T., Liang, X., Bi, P. & Kuang, S. Myostatin knockout drives browning of white adipose tissue through activating the AMPK-PGC1\u03b1-Fndc5 pathway in muscle. Faseb j. 27, 1981\u20131989 (2013).","journal-title":"Faseb j."},{"key":"BFsrep32495_CR43","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.bbrc.2009.07.129","volume":"388","author":"Y Chen","year":"2009","unstructured":"Chen, Y., Cao, L., Ye, J. & Zhu, D. Upregulation of myostatin gene expression in streptozotocin-induced type 1 diabetes mice is attenuated by insulin. Biochem. Biophys. Res. Commun. 388, 112\u2013116 (2009).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"BFsrep32495_CR44","first-page":"29","volume":"60","author":"W Wieteska-Skrzeczynska","year":"2009","unstructured":"Wieteska-Skrzeczynska, W., Grzelkowska-Kowalczyk, K., Jank, M. & Maciejewski, H. Transcriptional dysregulation of skeletal muscle protein metabolism in streptozotocin-diabetic mice. J. Physiol. Pharmacol. 60, 29\u201336 (2009).","journal-title":"J. Physiol. Pharmacol."},{"key":"BFsrep32495_CR45","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1007\/s00125-003-1116-6","volume":"46","author":"SP Laing","year":"2003","unstructured":"Laing, S. P. et al. Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes. Diabetologia 46, 760\u2013765 (2003).","journal-title":"Diabetologia"},{"key":"BFsrep32495_CR46","doi-asserted-by":"publisher","first-page":"271","DOI":"10.2337\/diab.33.3.271","volume":"33","author":"JS Dorman","year":"1984","unstructured":"Dorman J. S. et al. The Pittsburgh insulin-dependent diabetes mellitus (IDDM) morbidity and mortality study: mortality results. Diabetes 33, 271\u2013276 (1984).","journal-title":"Diabetes"},{"key":"BFsrep32495_CR47","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1161\/01.ATV.19.4.1014","volume":"19","author":"S Lehto","year":"1999","unstructured":"Lehto, S., R\u00f6nnemaa, T., Py\u00f6r\u00e4l\u00e4, K. & Laakso, M. Poor glycemic control predicts coronary heart disease events in patients with type 1 diabetes without nephropathy. Arterioscler. Thromb. Vasc. Biol. 19, 1014\u20131019 (1999).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"BFsrep32495_CR48","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1089\/dia.2011.0046","volume":"13","author":"TC Rodrigues","year":"2011","unstructured":"Rodrigues, T. C. et al. Obesity and coronary artery calcium in diabetes: the coronary artery calcification in type 1 diabetes (CACTI) study. Diabetes Technol. Ther. 13, 991\u2013996 (2011).","journal-title":"Diabetes Technol. Ther."},{"key":"BFsrep32495_CR49","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1212\/WNL.0000000000001070","volume":"83","author":"E Lach-Trifilieff","year":"2014","unstructured":"Lach-Trifilieff, E. et al. Treatment of sporadic inclusion body myositis with bimagrumab. Neurology 83, 2239\u20132246 (2014).","journal-title":"Neurology"},{"key":"BFsrep32495_CR50","doi-asserted-by":"publisher","first-page":"14070","DOI":"10.1073\/pnas.0806993105","volume":"105","author":"X Yu","year":"2008","unstructured":"Yu, X., Park, B. H., Wang, M. Y., Wang, Z. V. & Unger, R. H. Making insulin-deficient type 1 diabetic rodents thrive without insulin. Proc. Natl. Acad. Sci. USA 105, 14070\u201314075 (2008).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFsrep32495_CR51","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1358\/dnp.2009.22.2.1303818","volume":"22","author":"EL Tobinick","year":"2009","unstructured":"Tobinick, E. L. The value of drug repositioning in the current pharmaceutical market. Drug News Perspect 22, 119\u2013125 (2009).","journal-title":"Drug News Perspect"},{"key":"BFsrep32495_CR52","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.cmet.2015.05.016","volume":"21","author":"AL Bujak","year":"2015","unstructured":"Bujak, A. L. et al. AMPK activation of muscle autophagy prevents fasting-induced hypoglycemia and myopathy during aging. Cell Metab. 21, 883\u2013890 (2015).","journal-title":"Cell Metab."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep32495","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep32495.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep32495.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T22:23:47Z","timestamp":1672871027000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep32495"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,1]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,10,17]]}},"alternative-id":["BFsrep32495"],"URL":"https:\/\/doi.org\/10.1038\/srep32495","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,1]]},"assertion":[{"value":"24 March 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"32495"}}